论文部分内容阅读
目的:研究DNA-PKcs和Bcl-2在急性白血病(AL)细胞中的表达及相关性。方法:采用免疫组化SP法检测62名初治AL患者骨髓白血病细胞DNA-PKcs和Bcl-2的表达。结果:DNA-PKcs在对化疗药物耐药患者白血病细胞中的表达率(51.5%)明显高于敏感组(20.7%),P<0.05。Bcl-2在对化疗药物耐药患者白血病细胞中的表达率(84.8%)明显高于敏感组(62.1%),P<0.05。耐药组患者的白血病细胞中DNA-PKcs(+)/Bcl-2(+),DNA-PKcs(+)/Bcl-2(-),DNA-PKcs(-)/Bcl-2(+)和DNA-PKcs(-)/Bcl-2(-)细胞的百分率分别是88.2%,33.3%,44.8%和30.0%,DNA-PKcs(+)/Bcl-2(+)与DNA-PKcs(+)/Bcl-2(-)、DNA-PKcs(-)/Bcl-2(+)和DNA-PKcs(-)/Bcl-2(-)之间差异均有统计学意义(P<0.05,P<0.01,P<0.01)。33名耐药组患者中,DNA-PKcs和Bcl-2的表达无相关性,r=0.171,P>0.05。29名敏感组患者中,DNA-PKcs和Bcl-2的表达呈负相关,r=-0.45,P<0.05。结论:DNA-PKcs可能下调Bcl-2的表达,AL患者的白血病细胞中DNA-PKcs和Bcl-2表达水平增高与临床耐药密切相关。
Objective: To study the expression and correlation of DNA-PKcs and Bcl-2 in acute leukemia (AL) cells. Methods: Immunohistochemical SP method was used to detect the expression of DNA-PKcs and Bcl-2 in bone marrow leukemia cells of 62 naive AL patients. Results: The expression rate of DNA-PKcs in leukemia cells resistant to chemotherapeutic drugs (51.5%) was significantly higher than that in sensitive group (20.7%), P <0.05. The expression of Bcl-2 in leukemia cells resistant to chemotherapeutic drugs was significantly higher than that in sensitive patients (62.1%, P <0.05). DNA-PKcs (+) / Bcl-2 (-), DNA-PKcs (-) / Bcl-2 The percentages of DNA-PKcs (-) / Bcl-2 (-) cells were 88.2%, 33.3%, 44.8% and 30.0% (P <0.05, P <0.05, P <0.05), but there was no significant difference between DNA-PKcs (-) / Bcl- 0.01, P <0.01). There was no correlation between the expression of DNA-PKcs and Bcl-2 in 33 drug-resistant patients (r = 0.171, P> 0.05). The expression of DNA-PKcs and Bcl- = -0.45, P <0.05. Conclusion: DNA-PKcs may down-regulate the expression of Bcl-2. The increased expression of DNA-PKcs and Bcl-2 in leukemia cells of AL patients is closely related to clinical resistance.